GENEVA, November 9, 2011 -
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that it has further expanded its relationship with Ablynx and entered into a third agreement to co-discover and co-develop Nanobodies® against two targets in osteoarthritis. The companies will exploit the unique Nanobody features and will develop multi-specific products, which have extended half-lives.
TM Forum’s Frameworx Conformance Certified Solution Enables Accelerated Deployment of Innovative Cable Services
Comprehensive and Integrated Policy Management Product Enables Providers to Ease Network Congestion and Grow Service Revenues
New Applications Reduce Service Provider OPEX by Optimizing Network Interoperability and Accelerating Service Delivery
